Real estate round-up: Tyler Perry, Greenbriar megaproject and a new hotel
Here's your development round-up.
🎬 Tyler Perry Land: The Atlanta-based media mogul is planning an entertainment district totaling up to 1.3 million square feet on 38 acres he owns at Fort McPherson, according to a state filing.
The property is adjacent to Perry's 330-acre studio complex. The project would include a "variety of building uses, including office space, retail space, theatre, and associated parking."
🏡 Greenbriar's mega project: A New York-based developer wants to build more than 1,000 apartments and 250,000 square-feet of retail on 26 acres near Greenbriar Mall, the AJC reports.
Invest Atlanta, the city's economic development arm, approved a $5 million loan to help New York-based developer Mural Real Estate Partners purchase the land that straddles Atlanta and East Point.
In December 2024, Develop Fulton, the county's development authority, gave preliminary approval to a $23 million tax break for " Project Nexus," a code-named and secretive real estate deal that lines up with Mural's plans.
🏨 Origin's story: A South Downtown hotel that long sat in construction limbo is now open for business.
Origin Hotel Atlanta, a Wyndham hotel, sits blocks away from City Hall and the Georgia Capitol in South Downtown, a likely hub during the FIFA World Cup.
Features include an onsite restaurant and bar, gym and a top-floor event space with skyline views.
🌳 Fairburn mixed-use plan: Portman Holdings is moving forward with Meadow Glen Village, a 323-unit apartment community with a town green and space for retail and restaurants.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Design Limitless by Hyperlink InfoSystem Becomes a One-Stop Creative Partner for Branding, UI/UX, Motion Graphics & More
NEW YORK and LONDON, Aug. 7, 2025 /PRNewswire/ -- In a time when design plays a defining role in how brands are perceived, Design Limitless, powered by global tech leader Hyperlink InfoSystem, is reshaping how businesses access high-quality creative services. From branding and motion graphics to UI/UX, social media creatives, and 3D design, Design Limitless offers a full suite of design solutions backed by an expert team and a streamlined, subscription-based model. The service is built to cater to the evolving needs of startups, agencies, and enterprises through three purpose-driven subscription plans. The Essentials Package is best suited for startups or small teams looking for reliable creative support without the high cost of hiring in-house designers. It includes unlimited design requests, one active task at a time, access to a dedicated project manager, and a turnaround time of 1 to 2 business days per request - providing a solid foundation for early-stage brand development. For businesses with more frequent or diverse design needs, the Standard Package offers increased flexibility and speed. It allows two active requests at a time and includes access to a broader range of creative services such as motion graphics, UI/UX design, and marketing collateral. This package is ideal for growing companies that need consistent output to fuel ongoing campaigns and product launches. The Enterprise Package is built for high-growth companies, marketing agencies, and large organizations that require top-tier creative support at scale. With up to four active requests at once, priority delivery, and access to senior-level designers, this package enables businesses to manage multiple complex projects efficiently — from high-end branding and 3D visuals to custom illustrations and advanced product design. Harnil Oza, CEO of Hyperlink InfoSystem, stated, "With Design Limitless, we're offering more than design - we're offering creative peace of mind. Businesses no longer need to worry about sourcing quality designers or missing deadlines. Our team becomes an extension of theirs, delivering consistent, high-impact creative work that aligns with their goals, timelines, and brand identity." Operating through a centralized dashboard with unlimited requests and revisions, Design Limitless is designed to simplify collaboration while maintaining creative excellence. Each subscription is backed by Hyperlink InfoSystem's decade-long experience and trusted delivery process, ensuring that every brand - no matter its size - gets access to world-class design support. To explore services, view the portfolio, or subscribe to a creative plan, visit or contact info@ About Hyperlink InfoSystem: Hyperlink InfoSystem is a prominent international enterprise excelling in IT solutions in many domains. Since its humble beginnings in 2011, its specialization in technologies has expanded across web development, mobile app development, enterprise software solutions, and now Artificial Intelligence (AI). With over 1200+ employees and a global presence in the USA, UK, UAE, France, India, and Canada, Hyperlink InfoSystem is dedicated to assisting corporations to leverage the complete power of technology to accomplish their goals. Contact Details:Hyperlink InfoSystemHarnil Oza+1-309-791-4105info@ York Address:One World Trade Center285 Fulton Street suite 8500,New York, NY 10007,United StatesAhmedabad Address:C-308, Ganesh Meridian,Opp Kargil Petrol Pump, S.G. Highway,Sola, Ahmedabad, 380061IndiaLondon Address:Level 30, The Leadenhall Building,122 Leadenhall Street,London EC3V 4ABCanada Address:151 Yonge Street, 11th Floor,Toronto, Ontario, M5C 2W7,Canada Logo: View original content: SOURCE Hyperlink InfoSystem
Yahoo
6 minutes ago
- Yahoo
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda
The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complexities and pricing pressures. Major players like Pfizer, Merck, and Johnson & Johnson focus on developing effective treatments as demand surges due to an aging population. U.S. Pharmaceutical Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The "United States Pharmaceutical Market - Regulatory Insights & Forecast 2025-2033" report has been added to States Pharmaceutical Market is anticipated to grow to US$ 979.25 billion by 2033, compared to US$ 638.86 billion in 2024, growing at a CAGR of 4.86% during 2025-2033. The growth is attributed to growing demand for new medicines, greater incidence of chronic diseases, biotechnology advancement, and substantial R&D expenditure by leading pharmaceutical firms in therapeutic categories like oncology, neurology, and infectious diseases. Pharmaceuticals are medicines and drugs created for preventing, diagnosing, treating, and controlling different diseases and health ailments. They encompass prescription drugs, over-the-counter (OTC) medications, vaccines, and biologic drugs. The pharmaceutical sector entails intensive research and development (R&D), clinical testing, regulatory approval, and mass production to make drugs safe and the United States, drugs form the backbone of the healthcare system and are very popular as a result of high healthcare consciousness, superior medical infrastructure, and extensive availability of treatments. The U.S. harbors some of the world's biggest drug giants and pioneering biotech companies, and thus it is a world center for drug development. With an aging population and rising chronic illnesses such as diabetes and cancer, the demand for effective drugs continues to increase. Moreover, favorable government policies, robust patent protection, and insurance coverage further stimulate drug usage and development, cementing the industry's essential position in American health Drivers in the United States Pharmaceutical Market Aging Population & Chronic Disease PrevalenceThe American population is graying, which raises the incidence of chronic illnesses such as diabetes, cardiovascular disease, and neurodegenerative disease. Older people generally need constant medication management and specialized treatments. This age pattern directly enhances pharmaceutical product demand, particularly in therapeutic categories including oncology, diabetes, and cardiovascular medicine. As access to healthcare and diagnostic capabilities become better, more patients are prescribed drugs, further propelling drug consumption and revenue development throughout the market. The population of Americans aged 65 and over is expected to grow from 58 million in 2022 to 82 million in 2050 (a 47% increase), and the 65-and-older age group's proportion of the overall population is expected to grow from 17% to 23%.Biotech & Innovative Drug PipelineThe United States has a vibrant biotech community that is actively working on cell and gene therapies, immunotherapies, and RNA-based medicines. Breakthrough drugs - like CAR-T treatments and mRNA vaccines - are reaching the market faster than ever. Robust venture capital investment, public-private partnerships, and accelerated regulatory processes (e.g., FDA Fast Track) are driving pipeline development. The never-ending stream of high-value new medicines is powerfully driving pharmaceutical market growth. GlobalData's Drugs database of April 2025, indicates 8,684 investigational drugs currently in active development by up-and-coming pharmaceutical firms. Most of them, 46%, are in the preclinical phase, and 22% are at the discovery stage. In addition, many of these drugs are backed by firms that are new to the market or yet to be in Phase III Insurance & Reimbursement FrameworkThe broad coverage by the private insurers, Medicare, and Medicaid guarantees that most Americans are able to access prescription drugs. Reimbursement guidelines favoring newer, more expensive therapeutics - such as those for oncology and specialty treatments - spur medication use. Value-based contracting deals and volume purchasing by payors also reduce complexity in getting critical treatments. As reimbursement becomes more outcome-based and outcome-oriented, pharmaceutical firms are incentivized to create effective, high-impact medicines. In 2023 alone, the U.S. pharma industry invested more than USD 80 billion in R&D, a number that keeps increasing every year. Large firms such as Johnson & Johnson, Merck, and Eli Lilly have allotted substantial parts of their revenues to R&D, appreciating the need to formulate new medicines to address the needs of an aging population and a growing number of chronic in the United States Pharmaceutical Market Pricing Pressure & Regulatory ScrutinyUnaffordable drug prices in the U.S. have attracted mounting political and public attention. Policymakers are implementing provisions to manage pricing, such as drug price negotiation and out-of-pocket expense caps. These efforts introduce financial unpredictability for pharma firms. Aggressive negotiations between insurers and makers have accelerated requests for price rebates or discounts. Amidst this changing environment, pharmaceutical manufacturers must strike a balance between profitability and price compliance to remain competitive in the Regulatory EnvironmentWhile the FDA allows accelerated approval, development and post-marketing are still long and costly. Sophisticating regulatory demands - like more post-marketing studies and safety assessments - complicate things. Support of labeling changes, pharmacovigilance, and risk management programs raises operational costs. These issues chiefly jeopardize smaller biotech companies that might not have resources to comply with stringent FDA requirements, potentially holding up or derailing valuable therapy. Key Players Analysis: Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis F. Hoffmann-La Roche Ltd Novartis Ag Abbvie Inc. Johnson & Johnson Services, Inc. Merck & Co., Inc. Pfizer Inc. Bristol-Myers Squibb Company Sanofi GSK Plc. Takeda Pharmaceutical Company Limited Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $638.86 Billion Forecasted Market Value (USD) by 2033 $979.25 Billion Compound Annual Growth Rate 4.8% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. United States Pharmaceutical Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Molecule Type6.2 Product6.3 By Type6.4 By Disease6.5 By Route of Administration6.6 By Age Group6.7 By Distribution Channel6.8 By States7. Molecule Type7.1 Biologics & Biosimilars (Large Molecules)7.1.1 Market Analysis7.1.2 Market Size & Forecast7.2 Conventional Drugs (Small Molecules)8. Product8.1 Branded8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Generic9. Type9.1 Prescription9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 OTC9.2.1 Market Analysis9.2.2 Market Size & Forecast10. Disease10.1 Cardiovascular diseases10.1.1 Market Analysis10.1.2 Market Size & Forecast10.2 Cancer10.3 Diabetes10.4 Infectious diseases10.5 Neurological disorders10.6 Respiratory diseases10.7 Autoimmune diseases10.8 Mental health disorders10.9 Gastrointestinal disorders10.10 Women's Health Diseases10.11 Genetic and Rare genetic diseases10.12 Dermatological conditions10.13 Obesity10.14 Renal diseases10.15 Liver conditions10.16 Hematological disorders10.17 Eye conditions10.18 Infertility conditions10.19 Endocrine disorders10.20 Allergies10.21 Others11. Route of Administration11.1 Oral11.1.1 Market Analysis11.1.2 Market Size & Forecast11.2 Topical11.3 Parenteral11.4 Inhalations11.5 Other12. Age Group12.1 Children & Adolescents12.1.1 Market Analysis12.1.2 Market Size & Forecast12.2 Adults12.3 Geriatric13. Distribution Channel13.1 Hospital Pharmacy13.1.1 Market Analysis13.1.2 Market Size & Forecast13.2 Retail Pharmacy13.3 Others14. Top 10 States14.1 California14.1.1 Market Analysis14.1.2 Market Size & Forecast14.2 Texas14.3 New York14.4 Florida14.5 Illinois14.6 Pennsylvania14.7 Ohio14.8 Georgia14.9 Washington14.10 New Jersey14.11 Rest of United States15. Value Chain Analysis16. Porter's Five Forces Analysis16.1 Bargaining Power of Buyers16.2 Bargaining Power of Suppliers16.3 Degree of Competition16.4 Threat of New Entrants16.5 Threat of Substitutes17. SWOT Analysis17.1 Strength17.2 Weakness17.3 Opportunity17.4 Threats18. Pricing Benchmark Analysis18.1 F. Hoffmann-La Roche Ltd18.2 Novartis Ag18.3 Abbvie Inc.18.4 Johnson & Johnson Services, Inc.18.5 Merck & Co., Inc.18.6 Pfizer Inc.18.7 Bristol-Myers Squibb Company18.8 Sanofi18.9 GSK Plc.,18.10 Takeda Pharmaceutical Company Limited19. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Pharmaceutical Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Forbes
9 minutes ago
- Forbes
House Of Dior New York LaunchesThe LVMH-Led Brand's New Retail Concept
While the Dior Maison founded by Monsieur Christian Dior touts its home base on Avenue Montaigne in Paris where the brand was founded in 1947, the LVMH-owned marquee brand has just reopened and rebranded its New York flagship store on the Big Apple's premiere shopping corridor, 57th Street, which also harkens back to the brand's first US retail presence that opened in 1948 and was just 'steps away' according to a company release. Designed by house favorite architect Peter Marino, the new House of Dior New York location is the first in the world to house the designer labels' entire offerings, including women's, men's, beauty, and home, under one roof. Sitting at the corner of Madison, with the under-construction Louis Vuitton store just west on the 5th avenue corridor, the two flagships with their guaranteed impressive façades cement the Arnault family's retail might. Marino, for his part, leaned into his expertise in architecture and interior design and combined it with his in-depth knowledge of the French house, aiming for a customer experience that involves space, light, and a sensation of joy. "There is a French limestone façade and windows wrapping 57th St. and Madison Avenue, while inside we carved a double-height space to create this light and space. Instead of typical display windows, a garden was planted on this iconic corner referencing Christian Dior as a gardener and his gardens in Granville which are also part of Dior's brand DNA," Marino said via email adding, "There are VIP salons, an interior garden by Belgian landscaper Peter Wirtz, a café, Dior Maison, Dior Spa, dressed in works of art and unique and custom furniture. Dior is as passionate about art as I am. We have commissions from major artists such as Karine Laval, Jennifer Steinkamp, and Nir Hod, as well as unique artworks by Miriam Ellner, Robert Mapplethorpe, Jean-Michel Othoniel, Charles Jones, and Robert Polidori." With a pre-opening event allowing a sneak peek for VIP clients and press, guests discovered the four-story store which encompasses complete line offerings to include ready-to-wear and leather goods from Dior and Dior Homme collections, the last to be designed by Maria Grazia Chiuri and Kim Jones respectively, the fine jewelry offerings and Haute Joaillerie from Victoire de Castellane and the world of Dior Beauty to include the first Dior Spa in the US as well as the first to be housed within a store and Dior Maison accessible through a separate entrance on 57th Street. The expanded boutique also features the first Dior "Colorama"—the chromatic wall displays that, in this instance, feature 485 recreated styles from all categories throughout the brand's history—in the US and lines the circular staircases from the first to the second floor and the second to the third. While the previous store iteration separated the women's and men's stores, now they flow together, adjoined by the stairwell featuring the rainbow-like display. Throughout the store are fine art pieces Marino referenced, both existing and those created for the store, especially in a series of tableaus and wall-sized panels. For instance, on the main floor, a Niki de Saint Phalle sculpture accents a jewelry and small leather goods display case while a mother-of-pearl and rose quartz mural of a rose graces a spa salon. The color scheme for the women's space is a creamy white and gold with accents of silver and even rose gold. In contrast, the men's space is similarly rooted but features furniture in navy blue and grey with traditional Versailles parquet flooring throughout. The second and third floors feature VIP jewelry and ready-to-wear suites for women, with a first-of-its-kind in the US bespoke men's made-to-measure suiting service. Artwork includes pieces from Nir Hod and Tony Scherman, photographic works by Charles Jones and Robert Mapplethorpe, furniture crafted by Michele Oka Doner and Roland Mellan, Plum Blossom, a painting by Jean-Michel Othoniel, and River Blossom, an Eglomisé gilded panel and painting by Miriam Ellner. The fourth floor houses the magical retreat for the state-of-the-art luxury Dior Spa, which also features the complete line of Dior Beauty to include make-up, skincare, and fragrance, which Marino describes as "the ideal spa for myself or my friends." With its own entrance, Dior Maison is the first stand-alone boutique globally with its own dedicated space that features 35 customizable colors for its cannage and toile de Jouy dinnerware patterns, and a café setting featuring the Lily of the Valley dinnerware and glassware styles with pop-up courtesy of The Lowell Hotel serving coffee and tea. In a nod to the luxury group's sustainability efforts, the rest of the store's garden is peppered throughout the store via a flora and fauna delight made by Dior in house artisans from material scraps such as leathers, zippers, fringe trims and the brand's signature monogram fabrics to create flowers, trees and a Noah's Ark-worthy array of woodland creatures such as squirrels, foxes, a peacock, pigeons, butterflies and a mechanical woodpecker tapping away at the one of upcycled material trees. The brand's bee insignia, also a symbol for France, was bestowed upon guests as a memento of a slice of Granville in Midtown Manhattan.
